Literature DB >> 12709323

Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes.

Oscar Marchetti1, Philippe Moreillon, Josè M Entenza, Jacques Vouillamoz, Michel P Glauser, Jacques Bille, Dominique Sanglard.   

Abstract

The combination of fluconazole (FLC) and cyclosporine (CY) is fungicidal in FLC-susceptible C. albicans (O. Marchetti, P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard, Antimicrob. Agents Chemother. 44:2373-2381, 2000). The mechanism of this synergism is unknown. CY has several cellular targets including multidrug efflux transporters. The hypothesis that CY might inhibit FLC efflux was investigated by comparing the effect of FLC-CY in FLC-susceptible parent CAF2-1 (FLC MIC, 0.25 mg/liter) and in FLC-hypersusceptible mutant DSY1024 (FLC MIC, 0.03 mg/liter), in which the CDR1, CDR2, CaMDR1, and FLU1 transporter genes have been selectively deleted. We postulated that a loss of the fungicidal effect of FLC-CY in DSY1024 would confirm the roles of these efflux pumps. Time-kill curve studies showed a more potent fungistatic effect of FLC (P = 0.05 at 48 h with an inoculum of 10(3) CFU/ml) and a more rapid fungicidal effect of FLC-CY (P = 0.05 at 24 h with an inoculum of 10(3) CFU/ml) in the FLC-hypersusceptible mutant compared to those in the parent. Rats with experimental endocarditis were treated for 2 or 5 days with high-dose FLC, high-dose CY, or both drugs combined. FLC monotherapy for 5 days was more effective against the hypersusceptible mutant than against the parent. However, the addition of CY to FLC still conferred a therapeutic advantage in animals infected with mutant DSY1024, as indicated by better survival (P = 0.04 versus the results obtained with FLC) and sterilization of valves and kidneys after a very short (2-day) treatment (P = 0.009 and 0.002, respectively, versus the results obtained with FLC). Both in vitro and in vivo experiments consistently showed that the deletion of the four membrane transporters in DSY1024 did not result in loss of the fungicidal effect of FLC-CY. Yet, the accelerated killing in the mutant suggested a "dual-hit" mechanism involving FLC hypersusceptibility due to the efflux pump elimination and fungicidal activity conferred by CY. Thus, inhibition of multidrug efflux transporters encoded by CDR1, CDR2, CaMDR1, and FLU1 genes is not responsible for the fungicidal synergism of FLC-CY. Other cellular targets must be considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709323      PMCID: PMC153326          DOI: 10.1128/AAC.47.5.1565-1570.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  The mechanism of action of cyclosporin A and FK506.

Authors:  S Ho; N Clipstone; L Timmermann; J Northrop; I Graef; D Fiorentino; J Nourse; G R Crabtree
Journal:  Clin Immunol Immunopathol       Date:  1996-09

Review 2.  Cellular functions of immunophilins.

Authors:  A R Marks
Journal:  Physiol Rev       Date:  1996-07       Impact factor: 37.312

3.  Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals.

Authors:  A Voss; J A Kluytmans; J G Koeleman; L Spanjaard; C M Vandenbroucke-Grauls; H A Verbrugh; M C Vos; A Y Weersink; J A Hoogkamp-Korstanje; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

4.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

Authors:  D Sanglard; F Ischer; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Isogenic strain construction and gene mapping in Candida albicans.

Authors:  W A Fonzi; M Y Irwin
Journal:  Genetics       Date:  1993-07       Impact factor: 4.562

7.  Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits.

Authors:  K Chemlal; L Saint-Julien; V Joly; R Farinotti; N Seta; P Yeni; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

9.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

Authors:  A F List; C Spier; J Greer; S Wolff; J Hutter; R Dorr; S Salmon; B Futscher; M Baier; W Dalton
Journal:  J Clin Oncol       Date:  1993-09       Impact factor: 44.544

10.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

View more
  16 in total

1.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Authors:  William J Steinbach; Nina Singh; Jackie L Miller; Daniel K Benjamin; Wiley A Schell; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

Authors:  Eric Dannaoui; Patrick Schwarz; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 3.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

4.  Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.

Authors:  Dominique Sanglard; Alix T Coste
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

Review 5.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 6.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

7.  Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Marilena La Sorda; Riccardo Torelli; Barbara Fiori; Rosaria Santangelo; Giovanni Delogu; Giovanni Fadda
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

8.  Candida albicans biofilms produce antifungal-tolerant persister cells.

Authors:  Michael D LaFleur; Carol A Kumamoto; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-08-21       Impact factor: 5.191

9.  Unexpected link between iron and drug resistance of Candida spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells.

Authors:  Tulika Prasad; Aparna Chandra; Chinmay K Mukhopadhyay; Rajendra Prasad
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

10.  Role for cell density in antifungal drug resistance in Candida albicans biofilms.

Authors:  Palani Perumal; Satish Mekala; W LaJean Chaffin
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.